ANIXA BIOSCIENCES INC

NASDAQ: ANIX (Anixa Biosciences, Inc.)

最近更新时间: 12小时之前

2.71

0.04 (1.50%)

前收盘价格 2.67
成交量 287,727
股市价格/股市净资产 (P/B) 6.26
52周波幅
2.32 (-14%) — 5.46 (101%)
稀释每股收益 (EPS TTM) -0.380
总债务/股东权益 (D/E MRQ) 1.48%
流动比率 (MRQ) 8.89
营业现金流 (OCF TTM) -7.98 M
杠杆自由现金流 (LFCF TTM) -3.59 M
资产报酬率 (ROA TTM) -39.75%
股东权益报酬率 (ROE TTM) -65.38%

AIStockmoo 评分

-1.6
资本回报低于资本成本。资本回报下降。 参考
负债低。盈利能力弱。短期流动性充足。现金流为负。 参考
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
持仓估值 参考 NA
风险溢价 参考 NA
市场估值 参考 NA
过去一年呈下降趋势。股价远低于52周高点。 参考
下降趋势,但均线已走平。近期突破阻力位尚未获得确认。 参考
来自我们对走势图的 AI 技术分析。 参考 NA
近期没有目标价,因此依据目标价的调整方向。 参考
持仓情绪 参考 NA
新闻情绪 参考 NA
机构在最新13F申报中净+3.85%的股份:38家增持,13家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化+64.0%,回补天数8.4天(FINRA)。 参考
内部交易活动 参考 NA
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向一致,评分因此加强。
近期出现看涨反转形态:倒锤子线。 参考
低于中期趋势线。 参考
股价低于其52周平均水平。5年来下跌。 参考
短、中、长期趋势均向下。短期动能下降。 参考
股价接近支撑位。 参考
最终评分 -1.55
全部展开

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看涨
Biotechnology (全球的) 混合的 看涨
股票 Anixa Biosciences, Inc. 混合的 看涨

相关股票

股票 市值 DY P/E(TTM) P/B 评分
ANIX - - - 6.26 -1.6
HLVX 103 M - - 0.710 0.0
MEIP 49 M - - - 0.0
SONN 33 M - - 2.07 -1.4
INAB - - - 0.570 -2.5
PLRX - - - 0.320 -3.8

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 5.32%
机构持股比例 17.60%

所有权

姓名 日期 持有股份
Laird Norton Wetherby Trust Company, Llc 30 Sep 2026 600,727
D.A. Davidson & Co. 30 Sep 2026 494,949

该时间范围内无数据。

该时间范围内无数据。

机构

机构持股比例: 22.72%

持仓变动 机构数 股数
增持 38 1,216,268
减持 13 111,190
新建仓 16 267,256
清仓 4 26,400

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 1,628,481 8.4
15 Oct 2026 1,661,781 6.4
30 Sep 2026 1,350,212 3.7
15 Sep 2026 1,054,934 2.7
31 Aug 2026 993,183 3.3
14 Aug 2026 977,973 6.3

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

1 正面 0 负面 1 中性
日期 类型 细节
18 Nov 2026 Yahoo Finance Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will work with Curia, a leading global contract development and manufacturing organization (CDMO), to provide formulation development…
04 Nov 2026 Yahoo Finance Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Robert Wenham, M.D., Chair of the Gynecologic Oncology Program at Moffitt Cancer Center ("Moffitt") and principal investigator of…
26 Oct 2026 Yahoo Finance Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth cohort in its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129)…
13 Oct 2026 Yahoo Finance Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine
Learn how Anixa is advancing two clinical-stage oncology programs through differentiated immunotherapy and vaccine approachesManagement to discuss CAR-T clinical progress, completed Phase 1 breast cancer vaccine trial, planned Phase 2 development, and upcoming milestonesORLANDO, FL / ACCESS…
13 Oct 2026 Yahoo Finance Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026…
05 Oct 2026 Yahoo Finance Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian…
01 Oct 2026 Yahoo Finance Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov…
21 Sep 2026 Yahoo Finance Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued Patent Number 2020221280 related to Anixa's breast cancer vaccine technology, exclusively licensed from…
16 Sep 2026 Yahoo Finance Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board.
11 Sep 2026 Yahoo Finance Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc.
09 Sep 2026 Yahoo Finance Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the…
03 Sep 2026 Yahoo Finance Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO, has been invited to speak at the Nasdaq & LD Micro Inaugural SF Summit on Wednesday, September 9…
24 Aug 2026 Yahoo Finance Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference being held September 9 – 11, 2026, in New York…
显示更多

近期信号 K线形态与EMA交叉

▲ 倒锤子线 短期 · 日线 · 2个交易日前 · 16 Nov
下跌后出现小实体和长上影线:买方在试探上方。需要下一交易日收高确认。
▼ EMA看跌交叉 4个交易日前 · 12 Nov
短期 · EMA 7/20
7日EMA下穿20日EMA:短期动能转弱。
▼ EMA看跌交叉 3个交易日前 · 13 Nov
中期 · EMA 20/50
20日EMA下穿50日EMA:中期趋势转为向下。

技术形态 中期

趋势排列
斜率 –
入场位置 –
成交量
下降趋势,但均线已走平。近期突破阻力位尚未获得确认。
最近支撑: 2.49 – 2.71 · 强 · 多次测试,可能失守
最近阻力: 2.72 – 2.99 · 强

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票